Drug class

Metabolic Disease Enzyme Replacement - Mucopolysaccharidosis

Metabolic Disease Enzyme Replacement - Mucopolysaccharidosis is a formulary and compendial drug classification rather than a formal standalone pharmacologic class, grouping exogenous recombinant enzymes formulated to treat mucopolysaccharidoses (MPS). Read more about Metabolic Disease Enzyme Replacement - Mucopolysaccharidosis

6 drugs in this class 5 manufacturers

Related classes & indications

Antirheumatic Agents (Biologic DMARDS)Biologics, antibodies & cell therapy · 170 prescription drugs Immunomodulator, B-Lymphocyte Stimulator (BLyS)-Spec InhibBiologics, antibodies & cell therapy · 38 prescription drugs Mucopolysaccharidosis Type IiTop indication · 2 prescription drugs

Showing 1–6 of 6 drugs

Sort

ALDURAZYME (laronidase)

METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS · MUCOPOLYSACCHARIDOSIS TYPE I

GENZYME

NAGLAZYME (galsulfase)

METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS · MAROTEAUX-LAMY SYNDROME

BIOMARIN PHARMA

ELAPRASE (idursulfase)

METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS · MUCOPOLYSACCHARIDOSIS TYPE II

SHIRE US INC.

VIMIZIM (elosulfase alfa)

METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS · MUCOPOLYSACCHARIDOSIS TYPE IV-A

BIOMARIN PHARMA

MEPSEVII (vestronidase alfa-vjbk)

METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS · MUCOPOLYSACCHARIDOSIS TYPE VII

ULTRAGENYX PHAR

AVLAYAH (tividenofusp alfa-eknm)

METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS · MUCOPOLYSACCHARIDOSIS TYPE II

DENALI THERAPEU

Filter & compare in the drug finder → Opens the drug finder with Metabolic Disease Enzyme Replacement - Mucopolysaccharidosis preselected. Add indication or manufacturer filters there.

About Metabolic Disease Enzyme Replacement - Mucopolysaccharidosis.

Agents within this category—such as laronidase, idursulfase, elosulfase alfa, galsulfase, and vestronidase alfa—function by restoring deficient lysosomal hydrolase activity via receptor-mediated cellular uptake.

This mechanism facilitates the catabolism and clearance of accumulated glycosaminoglycans within tissues.

Consequently, these therapies are primarily indicated for managing the non-neurological, systemic manifestations of specific inherited lysosomal storage disorders, including MPS I, II, IVA, VI, and VII.

berkeley.edu
Metabolic Disease Enzyme Replacement - Mucopolysaccharidosis is a formulary and compendial drug classification rather than a formal standalone pharmacologic class, grouping exogenous recombinant enzymes formulated to treat mucopolysaccharidoses (MPS) Agents within this category—such as laronidase, idursulfase, elosulfase alfa, galsulfase, and vestronidase alfa—function by restoring deficient lysosomal hydrolase activity via receptor-mediated cellular uptake
michigan.gov
Metabolic Disease Enzyme Replacement - Mucopolysaccharidosis is a formulary and compendial drug classification rather than a formal standalone pharmacologic class, grouping exogenous recombinant enzymes formulated to treat mucopolysaccharidoses (MPS) Agents within this category—such as laronidase, idursulfase, elosulfase alfa, galsulfase, and vestronidase alfa—function by restoring deficient lysosomal hydrolase activity via receptor-mediated cellular uptake Consequently, these therapies are prim...
nih.gov
Metabolic Disease Enzyme Replacement - Mucopolysaccharidosis is a formulary and compendial drug classification rather than a formal standalone pharmacologic class, grouping exogenous recombinant enzymes formulated to treat mucopolysaccharidoses (MPS) This mechanism facilitates the catabolism and clearance of accumulated glycosaminoglycans within tissues
wellfleetrx.com
Agents within this category—such as laronidase, idursulfase, elosulfase alfa, galsulfase, and vestronidase alfa—function by restoring deficient lysosomal hydrolase activity via receptor-mediated cellular uptake Consequently, these therapies are primarily indicated for managing the non-neurological, systemic manifestations of specific inherited lysosomal storage disorders, including MPS I, II, IVA, VI, and VII
delveinsight.com
This mechanism facilitates the catabolism and clearance of accumulated glycosaminoglycans within tissues Consequently, these therapies are primarily indicated for managing the non-neurological, systemic manifestations of specific inherited lysosomal storage disorders, including MPS I, II, IVA, VI, and VII
mountsinai.org
This mechanism facilitates the catabolism and clearance of accumulated glycosaminoglycans within tissues
checkrare.com
Consequently, these therapies are primarily indicated for managing the non-neurological, systemic manifestations of specific inherited lysosomal storage disorders, including MPS I, II, IVA, VI, and VII